Pentostatin
- Generic Name
- Pentostatin
- Brand Names
- Nipent
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 53910-25-1
- Unique Ingredient Identifier
- 395575MZO7
- Background
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
- Indication
For the treatment of hairy cell leukaemia refractory to alpha interferon.
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia (HCL), Mycosis Fungoides (MF), Sezary Syndrome, Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Stage I Small Lymphocytic LymphomaStage II Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Small Lymphocytic LymphomaStage III Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaStage IV Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 82
- Registration Number
- NCT01024010
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00923845
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 68
- Registration Number
- NCT00816595
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
- Conditions
- Interventions
- Drug: cyclosporineDrug: mycophenolate mofetilDrug: pentostatinGenetic: cytogenetic analysisGenetic: fluorescence in situ hybridizationGenetic: protein analysisOther: flow cytometryOther: immunoenzyme techniqueOther: laboratory biomarker analysisOther: reduced-intensity transplant conditioning procedureProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation (PBSC)Radiation: total-body irradiation
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of Nebraska
- Registration Number
- NCT00816413
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 14
- Registration Number
- NCT00698685
- Locations
- 🇺🇸
Arizona Cancer Center at UMC North, Tucson, Arizona, United States
🇺🇸Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona, United States
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT00669318
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 45
- Registration Number
- NCT00602836
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 76
- Registration Number
- NCT00571662
- Locations
- 🇺🇸
University of Nebraska Medical Center, Section of Oncology/Hematology, Omaha, Nebraska, United States
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
- Conditions
- Interventions
- Biological: filgrastimBiological: pegfilgrastimBiological: rituximabBiological: sargramostimDrug: cyclophosphamideDrug: mitoxantrone hydrochlorideDrug: pentostatinGenetic: fluorescence in situ hybridizationGenetic: gene rearrangement analysisGenetic: polymerase chain reactionGenetic: protein expression analysisOther: flow cytometryProcedure: biopsy
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00546377
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00541034
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.